Shots:
- Bio-Thera has entered into an exclusive commercialization and licensing agreement with Gedeon Richter for BAT2206, a biosimilar version of Stelara (ustekinumab)
- Bio-Thera will handle development, manufacturing & supply of BAT2206 while Richter will have exclusive commercialization rights across the EU, UK, Switzerland & selected regions. Bio-Thera has already submitted regulatory filing with the EMA in Jul 2024
- Gedeon Richter will pay $8.5M upfront as well as ~$101.5M development & commercial milestones, contingent on meeting certain conditions
Ref: Bio-Thera and Gedeon Richter | Image: Bio-Thera and Gedeon Richter| Press Release
Related News:- Alvotech Reports the EMA’s Acceptance of MAA for AVT03 (Biosimilar, Prolia and Xgeva)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
